RU2760521C2 - Негенетическая модификация оболочечных вирусов - Google Patents
Негенетическая модификация оболочечных вирусов Download PDFInfo
- Publication number
- RU2760521C2 RU2760521C2 RU2019110407A RU2019110407A RU2760521C2 RU 2760521 C2 RU2760521 C2 RU 2760521C2 RU 2019110407 A RU2019110407 A RU 2019110407A RU 2019110407 A RU2019110407 A RU 2019110407A RU 2760521 C2 RU2760521 C2 RU 2760521C2
- Authority
- RU
- Russia
- Prior art keywords
- virus
- seq
- peptide
- tumor
- viral envelope
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616365.1A GB201616365D0 (en) | 2016-09-27 | 2016-09-27 | Non-genetic modification of enveloped viruses |
| GB1616365.1 | 2016-09-27 | ||
| PCT/EP2017/072366 WO2018059896A1 (en) | 2016-09-27 | 2017-09-06 | Non-genetic modification of enveloped viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019110407A RU2019110407A (ru) | 2020-10-29 |
| RU2019110407A3 RU2019110407A3 (cg-RX-API-DMAC7.html) | 2021-05-13 |
| RU2760521C2 true RU2760521C2 (ru) | 2021-11-26 |
Family
ID=57539741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019110407A RU2760521C2 (ru) | 2016-09-27 | 2017-09-06 | Негенетическая модификация оболочечных вирусов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10982194B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3519565A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7258746B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102599401B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109890957A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017337753B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019005825A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3035104A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201616365D0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2760521C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018059896A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201902388B (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
| EP3982980A4 (en) * | 2019-06-12 | 2023-11-29 | BioNTech US Inc. | NEOANTIGEN COMPOSITIONS AND USES THEREOF |
| CA3152796A1 (en) * | 2019-08-27 | 2021-03-04 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
| GB202013834D0 (en) * | 2020-09-03 | 2020-10-21 | Valo Therapeutics Oy | PeptiVAX therapy |
| AU2023367780A1 (en) | 2022-10-25 | 2025-03-27 | Barinthus Biotherapeutics North America, Inc. | Self-assembling nanoparticles |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 | |
| RU2245163C2 (ru) * | 1998-11-30 | 2005-01-27 | Сайтос Байотекнолэджи АГ | Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации |
| EA012984B1 (ru) * | 2003-12-17 | 2010-02-26 | Вайет | Конъюгаты иммуногенных пептидных носителей и способы их получения |
| RU2404993C2 (ru) * | 2003-07-02 | 2010-11-27 | Иннейт Фарма | Композиции и способы регуляции клеточной активности nk |
| RU2447145C2 (ru) * | 2006-11-13 | 2012-04-10 | Этерна Центарис ГмбХ | Микроорганизм-носитель нуклеотидных последовательностей, кодирующих антигены и белковые токсины |
| EP2349296A4 (en) * | 2008-08-21 | 2012-09-19 | Ottawa Hospital Res Inst | MANIPULATED SYNERGISTIC ONCOLYTIC VIRUS SYMBIOSIS |
| WO2015066042A1 (en) * | 2013-10-28 | 2015-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic hsv vector |
| RU2560976C2 (ru) * | 2009-05-12 | 2015-08-20 | Трансген Са | Способ продуцирования и очистки ортопоксвируса |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1108047A1 (en) | 1998-08-27 | 2001-06-20 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| KR100773109B1 (ko) | 1999-05-06 | 2007-11-02 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
| CA2390081C (en) * | 1999-10-29 | 2011-07-05 | University Of Southern California | Modified viral surface proteins which bind to cells of tumor vasculature |
| MXPA04005382A (es) * | 2001-11-07 | 2005-02-24 | Mannkind Corp | Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno. |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| WO2004000220A2 (en) | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| US20070243170A1 (en) * | 2002-10-07 | 2007-10-18 | The University Of Chicago | Targeting of Herpes Simplex Virus to Specific Receptors |
| CN101675993A (zh) * | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| US7432045B2 (en) * | 2003-12-01 | 2008-10-07 | Wisconsin Alumni Research Foundation | Method of inhibiting influenza infection with antiviral peptides |
| JP2008136381A (ja) * | 2006-11-30 | 2008-06-19 | Japan Health Science Foundation | 改変型アデノウイルスベクター及びその作製方法 |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| NO2700405T3 (cg-RX-API-DMAC7.html) * | 2008-05-29 | 2018-09-01 | ||
| ES2335077B1 (es) | 2008-12-30 | 2011-02-02 | Instituto Aragones De Ciencias De La Salud | Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores. |
| RU2013118723A (ru) | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| US20140140962A1 (en) | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| ES2847305T3 (es) * | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
| JP6705755B2 (ja) | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイValo Therapeutics Oy | 癌ワクチン開発のための改変アデノウイルス |
-
2016
- 2016-09-27 GB GBGB1616365.1A patent/GB201616365D0/en not_active Ceased
-
2017
- 2017-09-06 AU AU2017337753A patent/AU2017337753B2/en active Active
- 2017-09-06 JP JP2019515292A patent/JP7258746B2/ja active Active
- 2017-09-06 CN CN201780056649.7A patent/CN109890957A/zh active Pending
- 2017-09-06 BR BR112019005825-7A patent/BR112019005825A2/pt not_active Application Discontinuation
- 2017-09-06 KR KR1020197012062A patent/KR102599401B1/ko active Active
- 2017-09-06 WO PCT/EP2017/072366 patent/WO2018059896A1/en not_active Ceased
- 2017-09-06 RU RU2019110407A patent/RU2760521C2/ru active
- 2017-09-06 US US16/337,220 patent/US10982194B2/en active Active
- 2017-09-06 CA CA3035104A patent/CA3035104A1/en active Pending
- 2017-09-06 EP EP17765150.2A patent/EP3519565A1/en active Pending
-
2019
- 2019-04-15 ZA ZA2019/02388A patent/ZA201902388B/en unknown
-
2022
- 2022-12-09 JP JP2022197406A patent/JP2023029997A/ja active Pending
-
2023
- 2023-09-29 AU AU2023237201A patent/AU2023237201B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2245163C2 (ru) * | 1998-11-30 | 2005-01-27 | Сайтос Байотекнолэджи АГ | Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации |
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 | |
| RU2404993C2 (ru) * | 2003-07-02 | 2010-11-27 | Иннейт Фарма | Композиции и способы регуляции клеточной активности nk |
| EA012984B1 (ru) * | 2003-12-17 | 2010-02-26 | Вайет | Конъюгаты иммуногенных пептидных носителей и способы их получения |
| RU2447145C2 (ru) * | 2006-11-13 | 2012-04-10 | Этерна Центарис ГмбХ | Микроорганизм-носитель нуклеотидных последовательностей, кодирующих антигены и белковые токсины |
| EP2349296A4 (en) * | 2008-08-21 | 2012-09-19 | Ottawa Hospital Res Inst | MANIPULATED SYNERGISTIC ONCOLYTIC VIRUS SYMBIOSIS |
| RU2560976C2 (ru) * | 2009-05-12 | 2015-08-20 | Трансген Са | Способ продуцирования и очистки ортопоксвируса |
| WO2015066042A1 (en) * | 2013-10-28 | 2015-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic hsv vector |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019005825A2 (pt) | 2019-06-11 |
| RU2019110407A3 (cg-RX-API-DMAC7.html) | 2021-05-13 |
| AU2023237201A1 (en) | 2023-12-14 |
| AU2023237201B2 (en) | 2025-06-05 |
| JP2019532631A (ja) | 2019-11-14 |
| KR102599401B1 (ko) | 2023-11-06 |
| CA3035104A1 (en) | 2018-04-05 |
| ZA201902388B (en) | 2020-10-28 |
| JP2023029997A (ja) | 2023-03-07 |
| US20200010811A1 (en) | 2020-01-09 |
| WO2018059896A1 (en) | 2018-04-05 |
| JP7258746B2 (ja) | 2023-04-17 |
| EP3519565A1 (en) | 2019-08-07 |
| US10982194B2 (en) | 2021-04-20 |
| KR20190053260A (ko) | 2019-05-17 |
| GB201616365D0 (en) | 2016-11-09 |
| AU2017337753A1 (en) | 2019-03-21 |
| RU2019110407A (ru) | 2020-10-29 |
| AU2017337753B2 (en) | 2023-09-28 |
| CN109890957A (zh) | 2019-06-14 |
| NZ751251A (en) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamley | Peptides for vaccine development | |
| AU2023237201B2 (en) | Non-genetic modification of enveloped viruses | |
| Deres et al. | In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine | |
| AU2017234192B2 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | |
| KR100457647B1 (ko) | 펩티드및애쥬번트에기초한면역조절용약제학적조성물 | |
| KR20210104745A (ko) | 합성 펩티드 면역원에 대한 면역 자극제로서 인공 무차별적 t 헬퍼 세포 에피토프 | |
| US10925960B2 (en) | Antigen delivery system | |
| US20250230218A1 (en) | Pdl1 peptides for use in cancer vaccines | |
| RS61173B1 (sr) | Imunogeni wt-1 peptidi i postupci za njihovu upotrebu | |
| Sabatino | Medicinal chemistry and methodological advances in the development of peptide-based vaccines: miniperspective | |
| EP4210734A1 (en) | Heterologous prime boost vaccine | |
| McGuire et al. | A library-selected, Langerhans cell-targeting peptide enhances an immune response | |
| CN111295200A (zh) | 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒 | |
| Kim et al. | In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells | |
| Skea et al. | The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin | |
| Tohumeken et al. | A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response | |
| WO2022235678A1 (en) | Human anti-coronavirus peptide vaccines and methods of their use | |
| CN119156343A (zh) | 搭载肽的载体系统及其用途 | |
| EP3055322B1 (en) | Ubiquitinylated proteins | |
| Kim et al. | A single amino acid variation within an immunodominant AKR/Gross MuLV cytotoxic T-lymphocyte epitope leads to a loss in immunogenicity | |
| Ladjevardi et al. | Erika AK Fletcher, Robert A. Cordfunke, 3, 13 Aikaterini Nasi, Gunilla Törnqvist, Rob RPM Valentijn, 5 Anna Bergqvist, 4 Marita Westhrin, 4 Wenche Rasch, 4 Frida Lindqvist, Inken Dillmann, Martin Lord, Neanke Bouwman, 5 Jacques J. Neefjes, 6 Kees LMC Franken, 7 Stephanie McArdle, 8 Murrium Ahmad, 8 Silvia Johansson, 9, 10 Ferry Ossendorp, 3 Michael Haggman, 10, 11 Maria Lampinen, Gustav Ullenhag, 9, 10 | |
| Fletcher et al. | of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement | |
| Schultz et al. | peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides |